NEW YORK (Reuters) – Merck & Co Inc on Tuesday mentioned it can finish another late-stage trial of an Alzheimer’s drug as a result of it was unlikely to work, including to the pile-up of failures to seek out an efficient therapy for the mind-wasting illness.
The firm was testing the drug, Verubecestat, in sufferers with very early, or prodromal, Alzheimer’s illness. It scrapped the study nearly precisely one yr after ending a distinct late-stage trial of the identical drug in sufferers with gentle to average Alzheimer’s illness.
Verubecestat belongs to a category of experimental Alzheimer’s medication known as BACE1 inhibitors that concentrate on an enzyme concerned within the formation of the poisonous amyloid protein that turns into plaques within the brains of Alzheimer’s sufferers.
There have been plenty of high-profile failures in Alzheimer’s drug improvement in recent times. Pfizer Inc mentioned final month that it was abandoning analysis to seek out new medication geared toward treating Alzheimer’s and Parkinson’s illness.
Lilly beforehand endured a number of failures with its solanezumab, which additionally targets beta amyloid, however another way. In the newest setback, Lilly mentioned that drug didn’t sluggish declines in psychological capability of sufferers with even gentle signs.
Reporting by Michael ErmanEditing by Jonathan Oatis